Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rictor siRNA is a small interfering RNA (siRNA) designed to silence the expression of the Rictor (Rapamycin-insensitive companion of mTOR) gene. Rictor is an essential subunit of the mechanistic target of rapamycin complex 2 (mTORC2), which regulates cell survival, metabolism, and cytoskeleton organization. By knocking down Rictor, this siRNA inhibits the assembly and activity of mTORC2, leading to reduced phosphorylation of downstream targets such as Akt (at Ser473) and protein kinase C (PKC). In research settings, Rictor siRNA is used to investigate the role of the mTORC2 pathway in various conditions, including triple-negative breast cancer, glioblastoma, gastric cancer, and diabetic nephropathy. It has demonstrated the ability to suppress tumor cell proliferation, migration, and invasion, and to sensitize cells to apoptosis. Delivery systems such as graphene oxide nanoparticles have been explored to enhance its uptake and efficacy in tumor models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rictor siRNA.